Literature DB >> 10513835

Effects of nilvadipine on cytokine-levels and soluble factors in collagen disease complicated with essential hypertension.

H Kagawa1, S Nomura, Y Ozaki, M Nagahama, S Fukuhara.   

Abstract

We examined some immunological parameters, particularly cytokines and soluble factors in collagen diseases complicated with essential hypertension. We also investigated the effects of Nilvadipine on immunological parameters after treatment with this drug for six months. The frequency of helper/inducer T cells (CD4+ CD8- cells, CD4+ CD45RA- cells) decreased in the peripheral blood on a 6 month treatment with nilvadipine. There was a significant decrease of suppressor/inducer T cells (CD4+ 45RA+ cells), and an insignificant decrease of activated T cells (CD3+ HLA-DR+ cells) and memory T cells (CD45RA- CD45RO+ cells) after treatment. Before treatment with Nilvadipine, interleukin-1beta, tumor necrosis factor-a, and interleukin-6 levels increased higher in the patients than in healthy volunteers. However, interleukin-1beta and interleukin-6 concentrations tended to decrease after treatment with Nilvadipine. Besides, tumor necrosis factor-alpha decreased significantly after treatment. The soluble interleukin-2 receptor concentrations also showed a decreased tendency after treatment, although high concentrations were found in the patients before treatment. In contrast, soluble human leukocyte antigen-1 and soluble thrombomodulin levels showed no significant change after treatment. These results suggest that Nilvadipine inhibits the generation of cytokines derived from activated T lymphocytes. Nilvadipine, calcium antagonist, may be useful for inhibition of vascular complication in collagen diseases.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10513835     DOI: 10.3109/10641969909052196

Source DB:  PubMed          Journal:  Clin Exp Hypertens        ISSN: 1064-1963            Impact factor:   1.749


  4 in total

1.  Selective antihypertensive dihydropyridines lower Aβ accumulation by targeting both the production and the clearance of Aβ across the blood-brain barrier.

Authors:  Daniel Paris; Corbin Bachmeier; Nikunj Patel; Amita Quadros; Claude-Henry Volmar; Vincent Laporte; Jim Ganey; David Beaulieu-Abdelahad; Ghania Ait-Ghezala; Fiona Crawford; Michael J Mullan
Journal:  Mol Med       Date:  2010-12-17       Impact factor: 6.354

2.  European multicentre double-blind placebo-controlled trial of Nilvadipine in mild-to-moderate Alzheimer's disease-the substudy protocols: NILVAD frailty; NILVAD blood and genetic biomarkers; NILVAD cerebrospinal fluid biomarkers; NILVAD cerebral blood flow.

Authors:  Olga Meulenbroek; Sarah O'Dwyer; Daan de Jong; Gerrita van Spijker; Sean Kennelly; Fiona Cregg; Marcel Olde Rikkert; Laila Abdullah; Anders Wallin; Cathal Walsh; Robert Coen; Rose Anne Kenny; Leslie Daly; Ricardo Segurado; Anne Borjesson-Hanson; Fiona Crawford; Michael Mullan; Ugo Lucca; Rita Banzi; Florence Pasquier; Laetitia Breuilh; Matthias Riepe; Janos Kalman; William Molloy; Magda Tsolaki; Robert Howard; Jessica Adams; Siobhan Gaynor; Brian Lawlor
Journal:  BMJ Open       Date:  2016-07-19       Impact factor: 2.692

3.  NILVAD protocol: a European multicentre double-blind placebo-controlled trial of nilvadipine in mild-to-moderate Alzheimer's disease.

Authors:  Brian Lawlor; Sean Kennelly; Sarah O'Dwyer; Fiona Cregg; Cathal Walsh; Robert Coen; Rose Anne Kenny; Robert Howard; Caroline Murphy; Jessica Adams; Leslie Daly; Ricardo Segurado; Siobhan Gaynor; Fiona Crawford; Michael Mullan; Ugo Lucca; Rita Banzi; Florence Pasquier; Laetitia Breuilh; Matthias Riepe; Janos Kalman; Anders Wallin; Anne Borjesson; William Molloy; Magda Tsolaki; Marcel Olde Rikkert
Journal:  BMJ Open       Date:  2014-10-09       Impact factor: 2.692

4.  Nilvadipine in mild to moderate Alzheimer disease: A randomised controlled trial.

Authors:  Brian Lawlor; Ricardo Segurado; Sean Kennelly; Marcel G M Olde Rikkert; Robert Howard; Florence Pasquier; Anne Börjesson-Hanson; Magda Tsolaki; Ugo Lucca; D William Molloy; Robert Coen; Matthias W Riepe; János Kálmán; Rose Anne Kenny; Fiona Cregg; Sarah O'Dwyer; Cathal Walsh; Jessica Adams; Rita Banzi; Laetitia Breuilh; Leslie Daly; Suzanne Hendrix; Paul Aisen; Siobhan Gaynor; Ali Sheikhi; Diana G Taekema; Frans R Verhey; Raffaello Nemni; Flavio Nobili; Massimo Franceschi; Giovanni Frisoni; Orazio Zanetti; Anastasia Konsta; Orologas Anastasios; Styliani Nenopoulou; Fani Tsolaki-Tagaraki; Magdolna Pakaski; Olivier Dereeper; Vincent de la Sayette; Olivier Sénéchal; Isabelle Lavenu; Agnès Devendeville; Gauthier Calais; Fiona Crawford; Michael Mullan
Journal:  PLoS Med       Date:  2018-09-24       Impact factor: 11.069

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.